Clinical Cancer Research, Vol 2, Issue 9 1499-1508, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation

HSL Chan, G DeBoer, JJ Thiessen, A Budning, JE Kingston, JM O'Brien, G Koren, E Giesbrecht, G Haddad, Z Verjee, JL Hungerford, V Ling and BL Gallie
Divisions of Hematology-Oncology and Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children Research Institute, 555 University Avenue, Toronto, Ontario M5G 1X8 Canada.

Chemotherapy without radiation has not controlled most intraocular retinoblastoma, perhaps because of the common high expression of multidrug resistance P-glycoprotein that we found in retinoblastoma. Cyclosporin blocks P-glycoprotein-induced efflux of vincristine and teniposide in vitro, and possibly modulates responses to carboplatin. To avoid eye irradiation in bilateral retinoblastoma patients with RB1 germline mutations, which incurs a high second malignancy rate, we added cyclosporin A to a vincristine-teniposide-carboplatin protocol and consolidated chemotherapy responses with focal therapy. We scored patients requiring irradiation, enucleation, or focal ablation of central vision as failures. In 21 study patients, the overall relapse-free rate at a median follow-up of 3.3 years was 76%, with a rate of 92% for newly diagnosed and 50% for previously treated, relapsed retinoblastoma. Our results for the most unfavorable tumors with vitreous seeds (86% at 3.5 years) are better than published success rates of irradiation for similar tumors, or irradiation with the same chemotherapy without cyclosporin (45% at 2. 6 years). These results also exceeded our historic success rate with similar chemotherapy without cyclosporin, focal therapy, and/or radiation in 19 equivalently poor-risk patients (relapse-free rate 37% at a median follow-up of 5.6 years, P = 0.032), 16 of whom were previously untreated (relapse-free rate also 37%, P = 0.012). A better outcome occurred with higher cyclosporin blood levels and projected tissue exposure. Cyclosporin did not enhance the usual chemotoxicity. This clinical study suggests that cyclosporin improves the long-term response of retinoblastoma to chemotherapy, possibly by more than one mechanism.

This article has been cited by other articles:

				S E Chung, H S Sa, H H Koo, K H Yoo, K W Sung, and D-I Ham Clinical manifestations and treatment of retinoblastoma in Korea Br. J. Ophthalmol., September 1, 2008; 92(9): 1180 - 1184. [Abstract] [Full Text] [PDF]

				A. E. Rizzuti, I. J. Dunkel, and D. H. Abramson The Adverse Events of Chemotherapy for Retinoblastoma: What Are They? Do We Know? Arch Ophthalmol, June 1, 2008; 126(6): 862 - 865. [Full Text] [PDF]

				M. Chintagumpala, P. Chevez-Barrios, E. A. Paysse, S. E. Plon, and R. Hurwitz Retinoblastoma: Review of Current Management Oncologist, October 1, 2007; 12(10): 1237 - 1246. [Abstract] [Full Text] [PDF]

				S. Marchetti, R. Mazzanti, J. H. Beijnen, and J. H. M. Schellens Concise Review: Clinical Relevance of Drug Drug and Herb Drug Interactions Mediated by the ABC Transporter ABCB1 (MDR1, P-glycoprotein) Oncologist, August 1, 2007; 12(8): 927 - 941. [Abstract] [Full Text] [PDF]

				A. T. Meadows Retinoblastoma Survivors: Sarcomas and Surveillance J Natl Cancer Inst, January 3, 2007; 99(1): 3 - 5. [Full Text] [PDF]

				M. W. Wilson, C. H. Fraga, C. E. Fuller, C. Rodriguez-Galindo, J. Mancini, N. Hagedorn, M. L. Leggas, and C. F. Stewart Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1269 - 1273. [Abstract] [Full Text] [PDF]

				D H Abramson, S D Lawrence, K L Beaverson, T C Lee, I S Rollins, and I J Dunkel Systemic carboplatin for retinoblastoma: change in tumour size over time Br. J. Ophthalmol., December 1, 2005; 89(12): 1616 - 1619. [Abstract] [Full Text] [PDF]

				J. P. S. Filho, Z. M. S. Correa, A. N. Odashiro, A. B. Coutinho, M. C. Martins, C. M. Erwenne, and M. N. Burnier Jr Histopathological Features and P-glycoprotein Expression in Retinoblastoma Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3478 - 3483. [Abstract] [Full Text] [PDF]

				M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator Clin. Cancer Res., March 15, 2005; 11(6): 2320 - 2326. [Abstract] [Full Text] [PDF]

				L. A. Eckstein, K. R. Van Quill, S. K. Bui, M. S. Uusitalo, and J. M. O'Brien Cyclosporin A Inhibits Calcineurin/Nuclear Factor of Activated T-Cells Signaling and Induces Apoptosis in Retinoblastoma Cells Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 782 - 790. [Abstract] [Full Text] [PDF]

				S Krishnakumar, K Mallikarjuna, N Desai, A Muthialu, N Venkatesan, A Sundaram, V Khetan, and M P Shanmugam Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma Br. J. Ophthalmol., December 1, 2004; 88(12): 1521 - 1526. [Abstract] [Full Text] [PDF]

				B. C. Hayden, M.-E. Jockovich, T. G. Murray, M. Voigt, P. Milne, M. Kralinger, W. J. Feuer, E. Hernandez, and J.-M. Parel Pharmacokinetics of Systemic Versus Focal Carboplatin Chemotherapy in the Rabbit Eye: Possible Implication in the Treatment of Retinoblastoma Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3644 - 3649. [Abstract] [Full Text] [PDF]

				F. Munoz-Martinez, P. Lu, F. Cortes-Selva, J. M. Perez-Victoria, I. A. Jimenez, A. G. Ravelo, F. J. Sharom, F. Gamarro, and S. Castanys Celastraceae Sesquiterpenes as a New Class of Modulators That Bind Specifically to Human P-Glycoprotein and Reverse Cellular Multidrug Resistance Cancer Res., October 1, 2004; 64(19): 7130 - 7138. [Abstract] [Full Text] [PDF]

				A. Mulvihill, A. Budning, V. Jay, C. Vandenhoven, E. Heon, B. L. Gallie, and H. S. L. Chan Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma Arch Ophthalmol, August 1, 2003; 121(8): 1120 - 1124. [Abstract] [Full Text] [PDF]

				F. D. Camassei, R. Cozza, A. Acquaviva, A. Jenkner, L. Rava, R. Gareri, A. Donfrancesco, C. Bosman, P. Vadala, T. Hadjistilianou, et al. Expression of the Lipogenic Enzyme Fatty Acid Synthase (FAS) in Retinoblastoma and Its Correlation with Tumor Aggressiveness Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2399 - 2403. [Abstract] [Full Text] [PDF]

				C. Rodriguez-Galindo, M. W. Wilson, B. G. Haik, T. E. Merchant, C. A. Billups, N. Shah, A. Cain, J. Langston, M. Lipson, L. E. Kun, et al. Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin J. Clin. Oncol., May 15, 2003; 21(10): 2019 - 2025. [Abstract] [Full Text] [PDF]

				J. M. O'Brien Retinoblastoma: Clinical Presentation and the Role of Neuroimaging AJNR Am. J. Neuroradiol., March 1, 2001; 22(3): 427 - 429. [Full Text]

				D. Tomlinson The Treatment of Retinoblastoma: A Case Study Journal of Pediatric Oncology Nursing, March 1, 2001; 18(2): 50 - 54. [Abstract] [PDF]

				I. U. Scott, T. G. Murray, S. Toledano, and J. M. O'Brien New Retinoblastoma Tumors in Children Undergoing Systemic Chemotherapy Arch Ophthalmol, December 1, 1998; 116(12): 1685 - 1686. [Full Text] [PDF]